Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014674058> ?p ?o ?g. }
- W2014674058 endingPage "e29" @default.
- W2014674058 startingPage "e23" @default.
- W2014674058 abstract "The stimulatory role of estrogen on prolactin secretion and on proliferation of lactotropic cells is well established in terms of physiology but could this phenomenon be extended to include harmful effects of estrogens on prolactinoma? The aim of this review is to provide an up-to-date assessment of this subject with regard to pregnancy, use of contraceptive pills and postmenopausal hormone replacement therapy. Dopamine agonists allow women presenting prolactinoma to recover their ovulation cycles and become pregnant. There is no adverse data concerning the safety of dopamine agonists such as bromocriptine, if the woman is treated during the first trimester of pregnancy but there is little information regarding the most recent treatments such as cabergoline or quinagolide. In women with microadenomas, pregnancy generally has little impact on their adenoma, delivery is normal and breast-feeding is allowed. Concerning macroprolactinomas, tumor progression during pregnancy is a possible and endocrine follow-up remains necessary. Contraceptive pills containing estrogen and progestins are currently the best-tolerated and the most effective contraception. This type of contraceptive has long been avoided in patients presenting prolactinoma. While the literature has little to say on this subject and provides no adverse information, professional experience suggests that this attitude should be amended and that women presenting microprolactinoma should be allowed to use current contraceptive pills (containing 30 μg or less of ethinyl estradiol). The most important problem to overcome with this type of prescription, which masks the clinical consequences of hyperprolactinemia, is the possibility of overlooking hypophyseal disease that could result from this approach. The problem of macroprolactinoma is different; the possibility of prescribing contraceptive pills must be evaluated on a case-by-case basis and the impact of the drug on the adenoma must be very closely monitored. Estrogen replacement therapy in patients presenting hypogonadism should be attempted in patients with a history of prolactinoma and standard-monitoring precautions should be taken. In menopausal women, when replacement therapy is desirable, the presence of a microprolactinoma should not by itself avoid this prescription. The relationship between estrogens and prolactin has been known for a long time, in physiology. The stimulatory role of estradiol on prolactin cell's secretion by lactotropic cells and their subsequent growth is supported by numerous experimental and clinical data. Those experiments are the theoretical basis that has resulted for a long-standing fear from clinicians about hyperestrogenic contexts such as pregnancy as well as the use of contraceptive pills containing estrogens, and by analogy, all forms of replacement therapy containing estrogens in patients presenting prolactinoma. The aim of this review is to provide an up-to-date assessment of this question. This paper is part of the recent consensus of the French Endocrine Society (SFE) on prolactinomas. Le rôle stimulant des estrogènes sur la sécrétion de prolactine et sur la prolifération des cellules lactotropes est établi en physiologie, mais cet effet peut-il être élargi à un effet délétère des estrogènes sur les adénomes à prolactine ? L'objectif de cette revue est de faire le point actuel sur ce sujet chez la femme lors de la grossesse, la prise de contraception estroprogestative, et les traitements substitutifs hormonaux de ménopause. Les agonistes dopaminergiques permettent aux femmes qui souffrent d'un prolactinome de retrouver des cycles ovulatoires et d'être enceintes. Il n'existe aucune information péjorative concernant la tolérance des agonistes dopaminergiques au début de la grossesse, mais les informations manquent en ce qui concerne les traitements les plus récents comme la cabergoline et le quinagolide. Pour une femme présentant un microadénome, la grossesse n'a en règle générale pas d'impact sur l'adénome, l'accouchement doit être normal et l'allaitement est autorisé. En ce qui concerne les macroprolactinomes, une évolution tumorale pendant la grossesse reste possible et la surveillance en milieu endocrinologique reste nécessaire. La contraception estroprogestative est le type de contraception actuellement le mieux toléré et la plus efficace. Elle a longtemps été contre-indiquée chez les patientes présentant un prolactinome. La reprise de la littérature reste très pauvre à ce sujet et n'apporte pas d'éléments péjoratifs tandis que l'expérience professionnelle incite à revoir cette attitude et à permettre aux femmes présentant un microprolactinome d'utiliser les pilules actuelles (avec une dose d'éthynil estradiol inférieure ou égale à 30 μg). Le problème le plus important à résoudre avec cette prescription qui masque les conséquences cliniques de l'hyperprolactinémie sera la négligence envers la pathologie hypophysaire que cela risque d'induire. Le problème du macroprolactinome est différent, la possibilité de prescription d'une pilule sera ici évaluée individuellement et son impact sur l'adénome sera très surveillé. La substitution estrogénique chez une patiente avec un hypogonadisme doit être tentée chez une patiente aux antécédents de prolactinome avec les précautions de suivi habituelles. Chez une femme ménopausée, si le traitement substitutif est souhaitable, un antécédent de microprolactinome ne doit pas le contre-indiquer." @default.
- W2014674058 created "2016-06-24" @default.
- W2014674058 creator A5032547581 @default.
- W2014674058 creator A5047878606 @default.
- W2014674058 creator A5048846307 @default.
- W2014674058 creator A5084162832 @default.
- W2014674058 date "2007-06-01" @default.
- W2014674058 modified "2023-10-17" @default.
- W2014674058 title "Adénomes à prolactine et estrogènes: grossesse, contraception, traitement hormonal estroprogestatif" @default.
- W2014674058 cites W108798029 @default.
- W2014674058 cites W1890899313 @default.
- W2014674058 cites W1968457161 @default.
- W2014674058 cites W1970582318 @default.
- W2014674058 cites W1978966327 @default.
- W2014674058 cites W1979270155 @default.
- W2014674058 cites W1987610718 @default.
- W2014674058 cites W1996540480 @default.
- W2014674058 cites W2004306126 @default.
- W2014674058 cites W2011846252 @default.
- W2014674058 cites W2013027417 @default.
- W2014674058 cites W2013133422 @default.
- W2014674058 cites W2037255271 @default.
- W2014674058 cites W2039628906 @default.
- W2014674058 cites W2043563174 @default.
- W2014674058 cites W2043882730 @default.
- W2014674058 cites W2049238386 @default.
- W2014674058 cites W2050780353 @default.
- W2014674058 cites W2057971885 @default.
- W2014674058 cites W2058731555 @default.
- W2014674058 cites W2061844370 @default.
- W2014674058 cites W2063883908 @default.
- W2014674058 cites W2066763139 @default.
- W2014674058 cites W2069731260 @default.
- W2014674058 cites W2095301892 @default.
- W2014674058 cites W2113554315 @default.
- W2014674058 cites W2117639343 @default.
- W2014674058 cites W2121648298 @default.
- W2014674058 cites W2153683302 @default.
- W2014674058 cites W2158040636 @default.
- W2014674058 cites W2161513867 @default.
- W2014674058 cites W2417614720 @default.
- W2014674058 cites W2418826431 @default.
- W2014674058 doi "https://doi.org/10.1016/j.ando.2007.03.009" @default.
- W2014674058 hasPublicationYear "2007" @default.
- W2014674058 type Work @default.
- W2014674058 sameAs 2014674058 @default.
- W2014674058 citedByCount "3" @default.
- W2014674058 countsByYear W20146740582014 @default.
- W2014674058 countsByYear W20146740582015 @default.
- W2014674058 countsByYear W20146740582022 @default.
- W2014674058 crossrefType "journal-article" @default.
- W2014674058 hasAuthorship W2014674058A5032547581 @default.
- W2014674058 hasAuthorship W2014674058A5047878606 @default.
- W2014674058 hasAuthorship W2014674058A5048846307 @default.
- W2014674058 hasAuthorship W2014674058A5084162832 @default.
- W2014674058 hasConcept C126322002 @default.
- W2014674058 hasConcept C131872663 @default.
- W2014674058 hasConcept C197934379 @default.
- W2014674058 hasConcept C2776856834 @default.
- W2014674058 hasConcept C2777164284 @default.
- W2014674058 hasConcept C2778918492 @default.
- W2014674058 hasConcept C2779064019 @default.
- W2014674058 hasConcept C2779234561 @default.
- W2014674058 hasConcept C2779832395 @default.
- W2014674058 hasConcept C29456083 @default.
- W2014674058 hasConcept C54355233 @default.
- W2014674058 hasConcept C71315377 @default.
- W2014674058 hasConcept C71924100 @default.
- W2014674058 hasConcept C86803240 @default.
- W2014674058 hasConceptScore W2014674058C126322002 @default.
- W2014674058 hasConceptScore W2014674058C131872663 @default.
- W2014674058 hasConceptScore W2014674058C197934379 @default.
- W2014674058 hasConceptScore W2014674058C2776856834 @default.
- W2014674058 hasConceptScore W2014674058C2777164284 @default.
- W2014674058 hasConceptScore W2014674058C2778918492 @default.
- W2014674058 hasConceptScore W2014674058C2779064019 @default.
- W2014674058 hasConceptScore W2014674058C2779234561 @default.
- W2014674058 hasConceptScore W2014674058C2779832395 @default.
- W2014674058 hasConceptScore W2014674058C29456083 @default.
- W2014674058 hasConceptScore W2014674058C54355233 @default.
- W2014674058 hasConceptScore W2014674058C71315377 @default.
- W2014674058 hasConceptScore W2014674058C71924100 @default.
- W2014674058 hasConceptScore W2014674058C86803240 @default.
- W2014674058 hasIssue "2-3" @default.
- W2014674058 hasLocation W20146740581 @default.
- W2014674058 hasOpenAccess W2014674058 @default.
- W2014674058 hasPrimaryLocation W20146740581 @default.
- W2014674058 hasRelatedWork W2021147026 @default.
- W2014674058 hasRelatedWork W2029347554 @default.
- W2014674058 hasRelatedWork W2173645777 @default.
- W2014674058 hasRelatedWork W2469936039 @default.
- W2014674058 hasRelatedWork W2760233112 @default.
- W2014674058 hasRelatedWork W2979055614 @default.
- W2014674058 hasRelatedWork W4206317310 @default.
- W2014674058 hasRelatedWork W4212912088 @default.
- W2014674058 hasRelatedWork W4236050785 @default.
- W2014674058 hasRelatedWork W4244952737 @default.
- W2014674058 hasVolume "68" @default.